{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T14:07:00Z","timestamp":1778767620725,"version":"3.51.4"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"am","delay-in-days":382,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.therap.2021.02.006","type":"journal-article","created":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T17:22:13Z","timestamp":1614014533000},"page":"687-693","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Delayed thrombocytopenia following administration of abciximab: Pharmacovigilance survey and literature review"],"prefix":"10.1016","volume":"76","author":[{"given":"Louis","family":"Vincent","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphine","family":"Bourneau-Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana\u00efs","family":"Maurier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Babin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Delepine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Helley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lie","family":"Grandvuillemin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Lagarce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agn\u00e8s","family":"Lillo-Le Lou\u00ebt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Briet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2021.02.006_bib0130","series-title":"FDA, Company L and. Product Information: ReoPro(R) Intravenous Injection, Abciximab Intravenous Injection. Indianapolis","year":"2013"},{"key":"10.1016\/j.therap.2021.02.006_bib0135","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/01.CIR.89.2.596","article-title":"Randomized trial of a GPIIb\/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group","volume":"89","author":"Simoons","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.therap.2021.02.006_bib0140","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/j.1538-7836.2004.00744.x","article-title":"Delayed thrombocytopenia after treatment with abciximab: A distinct clinical entity associated with the immune response to the drug","volume":"2","author":"Curtis","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1016\/j.therap.2021.02.006_bib0145","article-title":"Delayed immune-mediated thrombocytopenia after re-exposure to abciximab therapy","volume":"27","author":"Rasti","year":"2011","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.therap.2021.02.006_bib0150","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3109\/09537104.2010.518324","article-title":"Profound delayed thrombocytopenia presenting 16 days after Abciximab (Reopro\u00ae) administration","volume":"22","author":"Webb","year":"2011","journal-title":"Platelets"},{"key":"10.1016\/j.therap.2021.02.006_bib0155","first-page":"486","article-title":"Severe delayed thrombocytopenia associated with abciximab (ReoPro) therapy","volume":"52","author":"Reddy","year":"2001","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.therap.2021.02.006_bib0160","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-219379","article-title":"Abciximab-induced delayed profound thrombocytopaenia","author":"Jbara","year":"2017","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.therap.2021.02.006_bib0165","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.hrtlng.2016.06.003","article-title":"Delayed severe abciximab-induced thrombocytopenia: A case report","volume":"45","author":"Pi\u0105tek","year":"2016","journal-title":"Heart Lung"},{"key":"10.1016\/j.therap.2021.02.006_bib0170","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3109\/09537104.2014.898181","article-title":"Delayed, severe thrombocytemia after abciximab infusion for primary angioplasty in acute coronary syndromes: Moving between systemic bleeding and stent thrombosis","volume":"26","author":"Giupponi","year":"2015","journal-title":"Platelets"},{"key":"10.1016\/j.therap.2021.02.006_bib0175","first-page":"E173","article-title":"Fatal delayed thrombocytopenia following abciximab therapy","volume":"18","author":"McCorry","year":"2006","journal-title":"J Invasive Cardiol"},{"key":"10.1016\/j.therap.2021.02.006_bib0180","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/107424840200700i103","article-title":"Delayed profound thrombocytopenia presenting 7 days after use of abciximab (ReoPro)","volume":"7","author":"Sharma","year":"2002","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.therap.2021.02.006_bib0185","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/146288401753514515","article-title":"Delayed thrombocytopenia following abciximab therapy","volume":"4","author":"Kaluski","year":"2001","journal-title":"Int J Cardiovasc Intervent"},{"key":"10.1016\/j.therap.2021.02.006_bib0190","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1160\/TH09-08-0603","article-title":"Thrombocytopenia after abciximab use results from different mechanisms","volume":"103","author":"Lajus","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.therap.2021.02.006_bib0195","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/01.CIR.97.12.1214","article-title":"Delayed profound thrombocytopenia after c7E3 Fab (Abciximab) therapy","volume":"97","author":"Jenkins","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.therap.2021.02.006_bib0200","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1182\/blood.V99.6.2054","article-title":"Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets","volume":"99","author":"Curtis","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.therap.2021.02.006_bib0205","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1160\/TH04-04-0237","article-title":"Delayed immunologic thrombocytopenia induced by abciximab","volume":"92","author":"Nurden","year":"2004","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.therap.2021.02.006_bib0210","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.amjcard.2003.12.051","article-title":"Final results of the ReoPro readministration registry","volume":"93","author":"Dery","year":"2004","journal-title":"Am J Cardiol"},{"issue":"8","key":"10.1016\/j.therap.2021.02.006_bib0215","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1161\/hc3301.094533","article-title":"Abciximab readministration: results of the reopro readministration registry","volume":"104","author":"Tcheng","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.therap.2021.02.006_bib0220","series-title":"Common Terminology Criteria for Adverse Events (CTCAE), version 5.0.Published November 27, 2017. U. S. Department of Health and Human Services","year":"2017"},{"key":"10.1016\/j.therap.2021.02.006_bib0225","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/ajh.23248","article-title":"Improving the specificity of the PF4 ELISA in diagnosing heparin-induced thrombocytopenia","volume":"87","author":"McFarland","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.therap.2021.02.006_bib0230","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood.V99.10.3540","article-title":"Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb\/IIIa antagonists is immune mediated","volume":"99","author":"Billheimer","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.therap.2021.02.006_bib0235","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2249.1994.tb06598.x","article-title":"Platelet surface IgG in patients receiving infusions of Fab fragments of a chimaeric monoclonal antibody to glycoprotein IIb-IIIa","volume":"98","author":"Chrisopoulos","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.therap.2021.02.006_bib0240","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1161\/01.CIR.97.17.1680","article-title":"Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb\/IIIa receptor blockade","volume":"97","author":"Mascelli","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.therap.2021.02.006_bib0245","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1182\/asheducation-2009.1.153","article-title":"Drug-induced thrombocytopenia: pathogenesis, evaluation, and management","author":"George","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.therap.2021.02.006_bib0250","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.tmrv.2013.05.005","article-title":"Approach to the diagnosis and management of drug-induced immune thrombocytopenia","volume":"27","author":"Arnold","year":"2013","journal-title":"Transfus Med Rev"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595721000743?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595721000743?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:56:00Z","timestamp":1758567360000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595721000743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0040595721000743"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2021.02.006","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Delayed thrombocytopenia following administration of abciximab: Pharmacovigilance survey and literature review","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2021.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}